Date published: 2025-11-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

RNF220 Inhibitors

The chemical class termed RNF220 Inhibitors encompasses a range of compounds that indirectly influence the function of RNF220, a ring finger protein integral to the ubiquitination process. These inhibitors, while not directly interacting with RNF220, exert their effects on the ubiquitin-proteasome system (UPS), thereby influencing the functional environment of RNF220. RNF220's role in ubiquitination, specifically as an E3 ubiquitin ligase, makes it a crucial component in the regulation of protein turnover. The indirect inhibition approach of these compounds affects various stages and elements of the UPS, altering the context within which RNF220 operates and impacting its efficiency and selectivity in tagging proteins for degradation.

RNF220 Inhibitors target key components and processes within the UPS, from the initiation of the ubiquitination cascade to the final degradation of proteins by the proteasome. This targeting can manifest in different ways: some inhibitors may interfere with the initiation stages of ubiquitination, affecting the conjugation and transfer of ubiquitin moieties, while others may impede the proteolytic activities of the proteasome. These disruptions can lead to altered protein turnover and ubiquitination dynamics, indirectly influencing the activity of E3 ligases like RNF220. Such alterations can have broad implications for cellular homeostasis, signaling pathways, and regulatory mechanisms in which RNF220 is involved. The second paragraph focuses on the broader implications of using these inhibitors. By modulating the ubiquitin-proteasome system, the inhibitors can impact the substrate specificity, regulation, and overall function of RNF220. This can lead to changes in the cellular balance of proteins, affecting various pathways and processes. Furthermore, these inhibitors can provide insights into the complex interplay between different components of the UPS and their collective impact on protein regulation. The indirect modulation of RNF220's activity through these inhibitors highlights the intricate nature of targeting specific components within a crucial regulatory system like the UPS. It underscores the nuanced strategies required to influence such a system and the effects on cellular function and protein homeostasis.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$56.00
$260.00
$980.00
163
(3)

A proteasome inhibitor that could indirectly affect RNF220 by altering the degradation of ubiquitinated proteins.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Another proteasome inhibitor, which could impact the ubiquitination process involving RNF220.

Lactacystin

133343-34-7sc-3575
sc-3575A
200 µg
1 mg
$165.00
$575.00
60
(2)

Inhibits the proteasome, potentially affecting the turnover of proteins ubiquitinated by RNF220.

Ubiquitin E1 Inhibitor, PYR-41

418805-02-4sc-358737
25 mg
$360.00
4
(1)

Inhibits the ubiquitin-activating enzyme E1, potentially impacting the ubiquitination process in which RNF220 is involved.

Thalidomide

50-35-1sc-201445
sc-201445A
100 mg
500 mg
$109.00
$350.00
8
(0)

Modulates the E3 ubiquitin ligase activity, potentially influencing the function of RNF220.

Lenalidomide

191732-72-6sc-218656
sc-218656A
sc-218656B
10 mg
100 mg
1 g
$49.00
$367.00
$2030.00
18
(1)

A derivative of thalidomide, can modulate the activity of E3 ubiquitin ligases, possibly affecting RNF220.

Pomalidomide

19171-19-8sc-364593
sc-364593A
sc-364593B
sc-364593C
sc-364593D
sc-364593E
5 mg
10 mg
50 mg
100 mg
500 mg
1 g
$98.00
$140.00
$306.00
$459.00
$1224.00
$1958.00
1
(1)

Another thalidomide analog, affects E3 ligases and could indirectly influence RNF220.

PF 4708671

1255517-76-0sc-361288
sc-361288A
10 mg
50 mg
$175.00
$700.00
9
(1)

Inhibits the deubiquitinating enzyme USP14, potentially impacting the ubiquitination process involving RNF220.